Maternus-Kliniken Aktiengesellschaft

XTRA:MAK Stock Report

Market Cap: €29.1m

Maternus-Kliniken Past Earnings Performance

Past criteria checks 0/6

Maternus-Kliniken's earnings have been declining at an average annual rate of -12.3%, while the Healthcare industry saw earnings growing at 7.2% annually. Revenues have been declining at an average rate of 3.9% per year.

Key information

-12.3%

Earnings growth rate

-12.5%

EPS growth rate

Healthcare Industry Growth15.7%
Revenue growth rate-3.9%
Return on equityn/a
Net Margin-6.3%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Maternus-Kliniken Aktiengesellschaft's (ETR:MAK) 25% Share Price Plunge Could Signal Some Risk

Aug 21
Maternus-Kliniken Aktiengesellschaft's (ETR:MAK) 25% Share Price Plunge Could Signal Some Risk

Maternus-Kliniken Aktiengesellschaft (ETR:MAK) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

Jul 05
Maternus-Kliniken Aktiengesellschaft (ETR:MAK) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

A Piece Of The Puzzle Missing From Maternus-Kliniken Aktiengesellschaft's (ETR:MAK) Share Price

Mar 13
A Piece Of The Puzzle Missing From Maternus-Kliniken Aktiengesellschaft's (ETR:MAK) Share Price

Maternus-Kliniken (ETR:MAK) Will Be Hoping To Turn Its Returns On Capital Around

Jul 27
Maternus-Kliniken (ETR:MAK) Will Be Hoping To Turn Its Returns On Capital Around

The Returns On Capital At Maternus-Kliniken (ETR:MAK) Don't Inspire Confidence

Feb 22
The Returns On Capital At Maternus-Kliniken (ETR:MAK) Don't Inspire Confidence

Some Investors May Be Worried About Maternus-Kliniken's (ETR:MAK) Returns On Capital

Jul 27
Some Investors May Be Worried About Maternus-Kliniken's (ETR:MAK) Returns On Capital

Estimating The Fair Value Of Maternus-Kliniken Aktiengesellschaft (ETR:MAK)

Jun 10
Estimating The Fair Value Of Maternus-Kliniken Aktiengesellschaft (ETR:MAK)

Revenue & Expenses Breakdown

How Maternus-Kliniken makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

XTRA:MAK Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 24109-700
31 Mar 24106-1100
31 Dec 23102-1400
30 Sep 23102-1700
30 Jun 23102-1900
31 Mar 23105-1600
31 Dec 22107-1400
30 Sep 22108-1000
30 Jun 22110-600
31 Mar 22111-400
31 Dec 21111-300
30 Sep 21114-500
30 Jun 21116-700
31 Mar 21115-800
31 Dec 20114-1000
30 Sep 20116-1010
30 Jun 20117-1020
31 Mar 20121-1030
31 Dec 19124-1050
30 Sep 19125-760
30 Jun 19125-580
31 Mar 19125-3110
31 Dec 18124-2130
30 Sep 18125-2170
30 Jun 18126-2210
31 Mar 18126-2170
31 Dec 17127-1140
30 Sep 171270140
30 Jun 171262140
31 Mar 171251140
31 Dec 161241140
30 Sep 161244210
30 Jun 161242140
31 Mar 161242140
31 Dec 151232140
30 Sep 1512328140
30 Jun 1512428140
31 Mar 1512328140
31 Dec 1412227140
30 Sep 14120-9150
30 Jun 14118-10150
31 Mar 14115-11150
31 Dec 13114-13150

Quality Earnings: MAK is currently unprofitable.

Growing Profit Margin: MAK is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: MAK is unprofitable, and losses have increased over the past 5 years at a rate of 12.3% per year.

Accelerating Growth: Unable to compare MAK's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MAK is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (40.5%).


Return on Equity

High ROE: MAK's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 06:06
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Maternus-Kliniken Aktiengesellschaft is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sven KuertenDz Bank Ag
Hartmut SchmidtHPS Research